Diabète
Articles
SFD 2024 : Flashback sur quelques séances marquantes
Diabète de type 1 : tous dans les starting blocks pour changer le cours de la maladie.
L'immunité au coeur des diabètes : un aspect central de la SFD 2024.
Focus sur la cellule beta / exploration de la pathogenèse du diabète.
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!
Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4
Time to Rethink T1D?
Start to think differently about Type 1 Diabetes by considering the pre-symptomatic stages of the condition and how it affects people of all ages and their families.
Autoimmune Type 1 Diabetes
The Type 1 Diabetes (T1D) field is evolving.
Recognition of the presymptomatic stages in T1D is growing.1-4
The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2
Infographic: Impact of Type 1 Diabetes Diagnosis
This infographic summarizes survey data* about the impact that families in Belgium and the Netherlands have felt when being diagnosed with autoimmune Type 1 Diabetes (T1D).
Detectability of Autoimmune Type 1 Diabetes
Systematic early detection of autoimmune Type 1 Diabetes might be a new way to avoid acute and chronic complications of the condition.1-5 This new approach may play a role as a revolutionary shift, helping to shape the future of Type 1 Diabetes management.2
The RESTORE-G Real World Evidence Study
RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2
Les contenus accessibles par ce site sont destinés exclusivement aux Professionnels de Santé.
Les contenus accessibles par ce site sont destinés
exclusivement aux Professionnels de Santé.
Sanofi met a votre disposition, sur un portail unique dédié aux professionnels de santé, des contenus exclusifs comprenant des contenus scientifiques et des outils pour votre pratique quotidienne.